NCT01987362View on ClinicalTrials.gov

A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 16, 2013

Primary Completion Date

October 11, 2017

Study Completion Date

October 11, 2017

Conditions
Solid Tumors, Advanced Solid Tumors
Interventions
DRUG

RO6870810

Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.

Trial Locations (4)

44106

University Hospitals of Cleveland, Cleveland

48201

Karmanos Cancer Center, Detroit

06520

Yale Cancer Center, New Haven

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01987362 - A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies | Biotech Hunter | Biotech Hunter